1. 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015) Authors: Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; Melemed, A.; Carter, G.C.; Zimmermann, A.H.; Treat, J.A.; Alexandris, E.; Lee, P.; Socinski, M.A.; Perol, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Real-world data on nivolumab treatment of non-small cell lung cancer. (4th March 2017) Authors: Brustugun, O.T.; Sprauten, M.; Helland, Å. Journal: Acta oncologica Issue: Volume 56:Number 3(2017) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗